| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CAPZb |
| Uniprot No | P47756 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-272aa |
| 氨基酸序列 | MSDQQLDCALDLMRRLPPQQIEKNLSDLIDLVPSLCEDLLSSVDQPLKIARDKVVGKDYLLCDYNRDGDSYRSPWSNKYDPPLEDGAMPSARLRKLEVEANNAFDQYRDLYFEGGVSSVYLWDLDHGFAGVILIKKAGDGSKKIKGCWDSIHVVEVQEKSSGRTAHYKLTSTVMLWLQTNKSGSGTMNLGGSLTRQMEKDETVSDCSPHIANIGRLVEDMENKIRSTLNEIYFGKTKDIVNGLRSVQTFADKSKQEALKNDLVEALKRKQQC |
| 预测分子量 | 57.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CAPZb重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: *"Purification and characterization of recombinant human F-actin capping protein subunits α1 and β"*
**作者**: Wear MA, Cooper JA
**摘要**: 该研究报道了人源CAPZb(β亚基)与α1亚基的重组表达及纯化方法，验证了重组蛋白在体外抑制肌动蛋白丝生长的功能，并分析了其结合细胞骨架的分子机制。
2. **文献名称**: *"Structural insights into the regulation of actin capping protein by phosphorylation and CARMIL"*
**作者**: Yadav S, Robinson RC
**摘要**: 通过重组CAPZb蛋白的晶体结构解析，揭示了磷酸化修饰及调控蛋白CARML对其活性的影响，阐明了其在细胞运动中的动态调控机制。
3. **文献名称**: *"Functional analysis of CAPZB in cancer cell migration via recombinant protein reconstitution"*
**作者**: Li H, et al.
**摘要**: 利用重组CAPZb蛋白进行功能实验，证明其通过稳定肌动蛋白网络抑制肿瘤细胞迁移，为靶向CAPZb的抗癌策略提供了理论依据。
注：以上文献为示例，实际引用时建议通过PubMed或专业数据库核对最新研究。
CAPZb, also known as F-actin-capping protein subunit beta, is a crucial regulatory component of the actin cytoskeleton in eukaryotic cells. It forms a heterodimer with its alpha subunit (CAPZa) to constitute the capping protein complex (CAPZ), which binds to the barbed ends of actin filaments, stabilizing them by preventing both elongation and depolymerization. This activity is essential for maintaining cytoskeletal architecture, cell motility, and intracellular trafficking. CAPZb's function extends to diverse cellular processes, including cell division, morphogenesis, and synaptic plasticity, with particular relevance in neuronal development and muscle contraction.
The recombinant CAPZb protein is produced through genetic engineering techniques, typically by expressing the cloned CAPZb gene in bacterial or mammalian expression systems. Recombinant technology enables high-purity, scalable production of the protein while preserving its native structure and biochemical properties. This has facilitated extensive in vitro studies on actin dynamics, allowing precise manipulation of CAPZb concentrations to investigate its kinetic effects on filament capping and interaction with other cytoskeletal regulators like profilin and formins.
Research on recombinant CAPZb has clinical implications, as dysregulation of actin capping is linked to pathologies including neurodegenerative diseases, cardiomyopathies, and cancer metastasis. Structural studies using recombinant protein have identified key residues involved in actin binding, informing drug discovery efforts targeting cytoskeletal abnormalities. Additionally, CAPZb serves as a tool protein in diagnostic assays for autoimmune disorders where anti-CAPZ antibodies are present. Ongoing studies explore its role in mechanotransduction and viral pathogenesis, underscoring its broad biological significance. The development of tagged recombinant variants (e.g., GFP-fusion or His-tagged) continues to enhance its utility in live-cell imaging and biochemical pull-down assays.
×
